Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | TK2 | O00142 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1417715 | 1.00 | TK1 (0.70) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL29408827 | 1.00 | TK1 (0.70) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL8693044 | 1.00 | TK1 (0.70) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL6270422 | 1.00 | TK1 (0.70) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL18032569 | 1.00 | TK1 (0.70) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL18032571 | 1.00 | TK1 (0.70) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL14459937 | 1.00 | TK1 (0.70) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL15740180 | 1.00 | TK1 (0.70) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL18032570 | 1.00 | TK1 (0.70) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL6270418 | 1.00 | TK1 (0.70) | TK1LMNASMN1; SMN2ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2708 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612662-B2 | DNA repair site detection for personal genomics, epigenomics, and gene therapy | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2026-04-28 | — | — | US | claimed |
| US-20260109989-A1 | COMPOSITIONS AND METHODS FOR THE SYNTHESIS AND IDENTIFICATION OF COVALENT APTAMERS | UNIV HAWAII (US) | 2026-04-23 | — | — | US | claimed |
| US-20260103824-A1 | Compositions and Methods for Selectively Synthesizing Triple-indexed cDNA Libraries | UNIV ROCKEFELLER (US) | 2026-04-16 | — | — | US | claimed |
| US-20260071273-A1 | METHODS FOR NUCLEIC ACID SEQUENCING | NANOHYB LLC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260062668-A1 | CLICK CHEMISTRY LIGAND | UNIV NORTHEASTERN (US) | 2026-03-05 | — | — | US | claimed |
| US-20260034158-A1 | METHODS OF TREATING CANCER OF THE CENTRAL NERVOUS SYSTEM COMPRISING 5-ETHYNYL-2'-DEOXYURIDINE | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2026-02-05 | — | — | US | claimed |
| EP-4622984-A1 | CLICK CHEMISTRY LIGAND | Northeastern University (US) | 2025-10-01 | — | — | EP | claimed |
| EP-4623073-A2 | METHODS FOR ASSESSING PROLIFERATION POTENCY OF GENE-EDITED T CELLS | Iovance Biotherapeutics, Inc. (US) | 2025-10-01 | — | — | EP | claimed |
| US-12371694-B2 | Compositions and methods for the synthesis and identification of covalent aptamers | UNIVERSITY OF HAWAII (US) | 2025-07-29 | — | — | US | claimed |
| EP-4558641-A1 | METHODS FOR DETECTION AND REDUCTION OF SAMPLE PREPARATION-INDUCED METHYLATION ARTIFACTS | Guardant Health, Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| WO-2016029889-A1 | METHOD OF DETERMINING THE ACTIVITY OF ENZYMES CONVERTING CYTOSINE DERIVATIVES TO URACIL DERIVATIVES IN CELLS, TISSUES AND ORGANISMS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-03-03 | — | — | WO | claimed |
| US-20160051690-A1 | METHODS FOR THE DEVELOPMENT OF VACCINES BASED ON OLIGOSACCHARIDE-OLIGONUCLEOTIDE CONJUGATES | UNIV BRANDEIS (US) | 2016-02-25 | — | — | US | claimed |
| WO-2015086818-A1 | OPTICALLY ACTIVATED RECEPTORS | IST AUSTRIA (INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA) (AT) | 2015-06-18 | — | — | WO | claimed |
| US-20150057243-A1 | Compositions and Methods for the Inhibition of Methyltransferases | NORTHERN UNIVERSITY (US) | 2015-02-26 | — | — | US | claimed |
| WO-2013151975-A1 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF METHYLTRANSFERASES | NORTHEASTERN UNIVERSITY (US) | 2013-10-10 | — | — | WO | claimed |
| US-6864049-B1 | Method for producing hybridization complexes whose stability is substantially independent of the base composition of two hybridized nucleic acid molecules | APPLIGENE-ONCOR S.A. (FR) | 2005-03-08 | — | — | US | claimed |
| US-5633360-A | CONTAINS AT LEAST TWO NUCLEOSIDE RESIDUES AND INTERNUCLEOTIDE LINKAGES | GILEAD SCIENCES, INC. (US) | 1997-05-27 | — | — | US | claimed |
| US-5137724-A | Active ingredient and potentiating ingredient; cytidine and vridine derivatives | STICHTING REGA VZW (BE) | 1992-08-11 | — | — | US | claimed |
| EP-0208550-B1 | ANTIVIRAL COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-05-22 | — | — | EP | claimed |
| EP-0208550-A2 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-01-14 | — | — | EP | claimed |